» Articles » PMID: 35159077

Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified As Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Feb 15
PMID 35159077
Authors
Affiliations
Soon will be listed here.
Abstract

The accurate prediction of malignancy for a pelvic mass detected on ultrasound allows for appropriate referral to specialised care. IOTA simple rules are one of the best methods but are inconclusive in 25% of cases, where subjective assessment by an expert sonographer is recommended but may not always be available. In the present paper, we evaluate the methods for assessing the nature of a pelvic mass, including IOTA with subjective assessment by expert ultrasound, RMI and ROMA. In particular, we investigate whether ROMA can replace expert ultrasound when IOTA is inconclusive. This prospective study involves one cancer centre and three general units. Women scheduled for an operation for a pelvic mass underwent a pelvic ultrasound pre-operatively. The final histology was obtained from the operative sample. The sensitivity, specificity and accuracy for each method were compared with the McNemar test. Of the 690 women included in the study, 171 (25%) had an inconclusive IOTA. In this group, expert ultrasound was more sensitive in diagnosing a malignant mass compared to ROMA (81% vs. 63%, = 0.009) with no significant difference in the specificity or accuracy. All assessment methods involving IOTA had similar accuracies and were more accurate than RMI or ROMA alone. In conclusion, when IOTA was inconclusive, assessment by expert ultrasound was more sensitive than ROMA, with similar specificity.

Citing Articles

Comparison of Two-Dimensional IOTA Simple Rules and Three-Dimensional Ultrasonography in Preoperative Assessment of Adnexal Masses.

Goel R, Singhal S, Manchanda S, Rajan S, Meena J, Bharti J Indian J Radiol Imaging. 2024; 34(4):588-595.

PMID: 39318565 PMC: 11419748. DOI: 10.1055/s-0044-1779734.


High-throughput viable circulating tumor cell isolation using tapered-slit membrane filter-based chipsets in the differential diagnosis of ovarian tumors.

Kim N, Suh D, Kim K, No J, Kim Y, Kim M PLoS One. 2024; 19(6):e0304704.

PMID: 38833451 PMC: 11149860. DOI: 10.1371/journal.pone.0304704.


High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.

Wilczynski J, Paradowska E, Wilczynski M Biomedicines. 2024; 12(1).

PMID: 38275400 PMC: 10813374. DOI: 10.3390/biomedicines12010229.


Diagnostic Performance of Ultrasound-Based International Ovarian Tumor Analysis Simple Rules and Assessment of Different NEoplasias in the adneXa Model for Predicting Malignancy in Women with Ovarian Tumors: A Prospective Cohort Study.

Rashmi N, Singh S, Begum J, Sable M Womens Health Rep (New Rochelle). 2023; 4(1):202-210.

PMID: 37139467 PMC: 10150711. DOI: 10.1089/whr.2022.0072.


Comparisons of Effectiveness in Differentiating Benign from Malignant Ovarian Masses between Conventional and Modified Risk of Malignancy Index (RMI).

Tantipalakorn C, Tinnangwattana D, Lerthiranwong T, Luewan S, Tongsong T Int J Environ Res Public Health. 2023; 20(1).

PMID: 36613208 PMC: 9820305. DOI: 10.3390/ijerph20010888.


References
1.
Timmerman D, Testa A, Bourne T, Ferrazzi E, Ameye L, Konstantinovic M . Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol. 2005; 23(34):8794-801. DOI: 10.1200/JCO.2005.01.7632. View

2.
Lycke M, Kristjansdottir B, Sundfeldt K . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018; 151(1):159-165. DOI: 10.1016/j.ygyno.2018.08.025. View

3.
Testa A, Kaijser J, Wynants L, Fischerova D, Van Holsbeke C, Franchi D . Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. Br J Cancer. 2014; 111(4):680-8. PMC: 4134495. DOI: 10.1038/bjc.2014.333. View

4.
Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter J, Schummer M, McIntosh M . The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63(13):3695-700. View

5.
Geomini P, Kruitwagen R, Bremer G, Cnossen J, Mol B . The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol. 2009; 113(2 Pt 1):384-94. DOI: 10.1097/AOG.0b013e318195ad17. View